Navigation Links
Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
Date:1/9/2012

NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells (CSCs), today announced that Eric K. Rowinsky, M.D. will join the Company as Executive Vice President, Chief Medical Officer and Head of Research and Development. Dr. Rowinsky will oversee the development and registration efforts for the Company's two clinical stage drug candidates, SL-401 and SL-701, as well as its preclinical pipeline.

"I am very excited to join Stemline at such an important time for the Company," said Dr. Rowinsky. He continued, "Not only is the Company's clinical stage pipeline extremely unique compared to other therapeutics in development, but both SL-401 and SL-701 are demonstrating objective anti-tumor activity in several malignancies that represent important unmet medical needs. I look forward to developing these novel agents to their fullest potential, advancing Stemline's programs towards potential global registration, and, in doing so, hopefully improving the lives of people with a variety of malignancies."

Ivan Bergstein, Stemline's Chief Executive Officer, said, "Dr. Rowinsky brings a wealth of drug development experience to the Stemline team and we look forward to his contribution and leadership in advancing our pipeline forward."

Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs from preclinical to regulatory approval. Among his many endeavors before joining Stemline was that of Executive Vice President and Chief Medical Officer for Imclone Systems, Inc., where he led the FDA approval of Erbitux® for head and neck and colorectal cancers, and advanced eight other monoclonal antibodies through clinical development. Before joining Imclone, Dr. Rowinsky was the Director of the Institute of Drug Development ("IDD") at the Cancer Therapy and Research Center. In addition,
'/>"/>

SOURCE Stemline Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... March 31, 2013, before market on Tuesday, May 28, 2013.  ... 28, 2013, at 8:00 a.m. EDT (May 28, 2013 at ... results and provide an update on recent corporate developments. ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
(Date:5/16/2013)... , May 16, 2013  Alere Inc. (NYSE: ... charge of their health at home through the merger of ... of $3.00 per share on its Series B Convertible Perpetual ... 15, 2013 to holders of record of Series B stock ... Such payment will cover the amount of all dividends ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Decline in Global Measles Deaths, Joint News Release: ... and WASHINGTON, Nov. 29, Measles deaths in Africa fell ... 396,000 to 36,000, reaching the,United Nations 2010 goal to ... spectacular gains achieved in Africa helped generate a strong,decline ...
... Nov. 29 AIDS Action Council,joins organizations and individuals ... 20th annual World AIDS Day, December 1, 2007. Since ... awareness,about the HIV/AIDS pandemic and to reinvigorate global, national, ... and 2008 theme of World AIDS Day is leadership. ...
Cached Medicine Technology:Measles Deaths in Africa Plunge by 91% 2Measles Deaths in Africa Plunge by 91% 3Measles Deaths in Africa Plunge by 91% 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2
(Date:5/19/2013)... SUNDAY, May 19 (HealthDay News) -- Although spring arrived ... the summer allergy season will still be strong, according ... at Birmingham. Dr. Richard Waguespack, clinical professor in ... often results in a robust summer allergy season. However, ... as sneezing, wheezing and coughing, he added. "Tree ...
(Date:5/19/2013)... St. Louis, MO (PRWEB) May 19, 2013 ... Member Conference, May 19-22, 2013, at the Walt Disney ... the latest trends in supply chain innovation, care delivery ... a much different dynamic in all healthcare markets, ... necessary part of the conversation,” said Todd Ebert, Amerinet ...
(Date:5/19/2013)... May 19, 2013 Actos lawsuit ... litigation now underway in U.S. District Court, Western District ... dated May 3rd, the Court has modified the litigation’s ... eight cases rather than four. The next Status Conference ... May 23rd. (In re: Actos Product Liability Litigation, MDL ...
(Date:5/19/2013)... May 19, 2013 According to ... Analysis and Forecast (2013 – 2018): By Applications ... Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) ... image sensor market was $8.00 billion in 2012 ... 2018, at an estimated CAGR of 3.84% from ...
(Date:5/19/2013)... Fat Burning Furnace developed by Rob ... people with fat burning diet plans, training ... Burning Furnace package, people will receive the Fat Burning ... quickly. The Fat Burning Furnace manual includes fat loss ... muscle mass. In addition, this book covers step-by-step instructions, ...
Breaking Medicine News(10 mins):Health News:Managing Seasonal Allergies 2Health News:Healthcare Leaders Gather at 2013 Amerinet Member Conference to Share New Ways to Reduce Costs and Enhance Care Delivery 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2
... ... biopsy techniques away from more invasive approaches toward imaging-guided percutaneous—or through the skin—techniques, according ... journal Radiology . , ... Oak Brook, IL (Vocus) June 29, 2010 -- Advanced imaging technologies ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... from several large clinical trials, the diabetes drug Avandia does ... argument that the drug,s risks might outweigh its benefits in ... however, show an increased risk for death from cardiovascular disease, ...
... HealthDay Reporter , MONDAY, June 28 (HealthDay News) -- ... drugs known as statins are a third less likely to ... that your doctor prescribe a statin -- drugs such ... The findings aren,t firm enough for doctors to make ...
... BROOK, Ill. Arthroscopic surgical repair of torn anterior cruciate ... not decrease the chances of developing osteoarthritis, according to a ... issue of the journal Radiology . A ... knee osteoarthritis was evident in patients, regardless of whether or ...
... children and teenagers for watching too much TV. It turns ... their time watching TV, and it is not good for ... Research on Aging and Rady School of Management at the ... a study published online in advance of publication in the ...
... review, led by Dr. Joseph Lee, published in the June 2010 ... Orthopaedic Surgeons ( JAAOS ) suggests that a herniated disk ... leg pain in adults, but surgery is not for everyone. ... pain at some point in their lives Disks, which are ...
Cached Medicine News:Health News:Use of Less Invasive, Imaging-Guided Biopsies on the Rise 2Health News:Use of Less Invasive, Imaging-Guided Biopsies on the Rise 3Health News:Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude 2Health News:Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude 3Health News:Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude 4Health News:Statins May Lower Rates of Prostate Cancer Recurrence 2Health News:Surgical repair of knee injuries does not decrease risk of osteoarthritis 2Health News:Older adults watch more TV than younger people, enjoy it less 2Health News:Lower back pain and surgery 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: